Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index

Cancer

Volumn 121, Issue 21, 2015, Pages 3818-3825

  Suh, Beomseok ^a   Yun, Jae Moon ^a   Park, Sehhoon ^a   Shin, Dong Wook ^a,b   Lee, Tae Hoon ^c   Yang, Hyung Kook ^d   Ahn, Eunmi ^a   Lee, Hyejin ^a,b   Park, Jin Ho ^a   Cho, Belong ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Cancer Hospital   (South Korea)

^c METROHEALTH MEDICAL CENTER   (United States)

^d National Cancer Center   (South Korea)

Author keywords

alcohol drinking; cancer screening; hepatocellular carcinoma; liver cirrhosis; liver fibrosis index

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL EVALUATION; COHORT ANALYSIS; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; DRINKING BEHAVIOR; ECHOGRAPHY; FEMALE; FIB-4 LIVER FIBROSIS INDEX; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; ADVERSE EFFECTS; AGED; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; COMPLICATION; INCIDENCE; LIVER FUNCTION TEST; LIVER NEOPLASMS; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84944728926     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29577     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C,. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008; 48: 137-145.
3. Jemal A, Simard EP, Dorell C, et al., Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013; 105: 175-201.
4. Jung KW, Park S, Kong HJ, et al., Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012; 44: 11-24.
5. Fattovich G, Stroffolini T, Zagni I, Donato F,. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127: S35-S50.
6. Morgan TR, Mandayam S, Jamal MM,. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004; 127: S87-S96.
7. Hassan MM, Hwang LY, Hatten CJ, et al., Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002; 36: 1206-1213.
8. Zhang BH, Yang BH, Tang ZY,. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130: 417-422.
9. Aghoram R, Cai P, Dickinson JA,. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012; 9: CD002799.
10. Park B, Choi KS, Lee YY, Jun JK, Seo HG,. Trends in cancer screening rates among Korean men and women: results from the Korean National Cancer Screening Survey (KNCSS), 2004-2011. Cancer Res Treat. 2012; 44: 113-120.
11. Nzeako UC, Goodman ZD, Ishak KG,. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol. 1996; 105: 65-75.
12. Chiesa R, Donato F, Tagger A, et al., Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev. 2000; 9: 213-216.
13. Martinez SM, Crespo G, Navasa M, Forns X,. Noninvasive assessment of liver fibrosis. Hepatology. 2011; 53: 325-335.
14. Naveau S, Gaude G, Asnacios A, et al., Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology. 2009; 49: 97-105.
15. Nunes D, Fleming C, Offner G, et al., Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol. 2010; 105: 1346-1353.
16. Ghany MG, Lok AS, Everhart JE, et al., Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 2010; 138: 136-146.
17. Park LS, Tate JP, Justice AC, et al., FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2512-2517.
18. Vallet-Pichard A, Mallet V, Nalpas B, et al., FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology. 2007; 46: 32-36.
19. Ohhira M, Fujimoto Y, Matsumoto A, Ohtake T, Ono M, Kohgo Y,. Hepatocellular carcinoma associated with alcoholic liver disease: a clinicopathological study and genetic polymorphism of aldehyde dehydrogenase 2. Alcohol Clin Exp Res. 1996; 20: 378A-382A.
20. Wilchesky M, Tamblyn RM, Huang A,. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004; 57: 131-141.
21. Word Health Organization. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney, Australia: Health Communications; 2000.
22. Korean Liver Cancer Study Group. J Korean Alcohol Liquor Ind. 1986; 6: 65-69.
23. Choong CC, Venkatesh SK, Siew EP,. Accuracy of routine clinical ultrasound for staging of liver fibrosis. J Clin Imaging Sci. 2012; 2: 58.
24. Harrell FE, Lee KL, Califf RM, Pryor DB, Rosati RA,. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984; 3: 143-152.
25. Yang HI, Sherman M, Su J, et al., Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010; 28: 2437-2444.
26. Mancebo A, Gonzalez-Dieguez ML, Cadahia V, et al., Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol. 2013; 11: 95-101.
27. Rehm J, Taylor B, Mohapatra S, et al., Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010; 29: 437-445.
28. Omata M, Lesmana LA, Tateishi R, et al., Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4: 439-474.
29. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
30. Zaman S, Johnson P, Williams R,. Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. Cancer. 1990; 65: 1607-1610.
31. Aube C, Oberti F, Korali N, et al., Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol. 1999; 30: 472-478.